Meeting
2024 ASCO Annual Meeting
Utidelone plus bevacizumab for the treatment of HER2-negative breast cancer brain metastases (U-BOMB): A multicenter, single-arm phase II study.
Authors
Min Yan
Department of Breast, Henan Cancer Hospital, Zhengzhou, China
Min Yan , Huimin Lv , Xinlan Liu , Geng Cuizhi , Shusen Wang , Yuhua Song , Zhenzhen Liu , Limin Niu , Mengwei Zhang , Yajing Feng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Non–Subtype-Specific Breast Cancer Therapies
Clinical Trial Registration Number
NCT05357417
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 1081)
DOI
10.1200/JCO.2024.42.16_suppl.1081
Abstract #
1081
Poster Bd #
59
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma.
First Author: Dale Randall Shepard
Poster
2014 ASCO Annual Meeting
SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer—A multicenter, randomized phase III trial.
First Author: Christoph Rochlitz
Poster
2024 ASCO Annual Meeting
First-line treatment preferences for advanced melanoma among oncologists and patients in the US: A discrete choice experiment.
First Author: Michael A. Postow
Poster
2024 ASCO Annual Meeting
A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183).
First Author: Maha H. A. Hussain